Amantadine Use for Postconcussion Syndrome

Ivan D. Carabenciov, Britta L. Bureau, Michael Cutrer, Rodolfo Savica

Research output: Contribution to journalArticle

Abstract

The development of postconcussion syndrome after traumatic brain injury can result in a wide range of potentially debilitating symptoms that includes headaches, cognitive dysfunction, and mood disorders. Unfortunately, data on helpful medications are quite limited, particularly on the treatment of persistent headaches attributed to trauma. This retrospective medical record review used data collected from patients with a diagnosis of postconcussion syndrome in Mayo Clinic's Neurology and Physical Medicine and Rehabilitation outpatient clinics to evaluate the response of postconcussive symptoms to amantadine. A complete trial of amantadine was defined as 100 mg twice per day for 2 months. Thirty-three patients were prescribed amantadine for postconcussive syndrome after traumatic brain injury. One-third of patients discontinued the medication because of adverse effects. However, posttraumatic headaches were improved in 80% of patients who completed a full trial of amantadine. Surprisingly, patients had improvement in headaches even if the medication was prescribed years after the initial trauma. Little improvement was noted in other symptoms such as poor memory, dizziness, and personality changes. Although additional research is certainly needed, amantadine may be a reasonable medication to consider for the treatment of persistent headaches attributed to trauma, even if the initial injury is remote.

Original languageEnglish (US)
Pages (from-to)275-277
Number of pages3
JournalMayo Clinic proceedings
Volume94
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Amantadine
Headache
Wounds and Injuries
Physical and Rehabilitation Medicine
Dizziness
Neurology
Ambulatory Care Facilities
Mood Disorders
Medical Records
Personality
Therapeutics
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Amantadine Use for Postconcussion Syndrome. / Carabenciov, Ivan D.; Bureau, Britta L.; Cutrer, Michael; Savica, Rodolfo.

In: Mayo Clinic proceedings, Vol. 94, No. 2, 01.02.2019, p. 275-277.

Research output: Contribution to journalArticle

Carabenciov, Ivan D. ; Bureau, Britta L. ; Cutrer, Michael ; Savica, Rodolfo. / Amantadine Use for Postconcussion Syndrome. In: Mayo Clinic proceedings. 2019 ; Vol. 94, No. 2. pp. 275-277.
@article{62e16f9651f74c8695ffb20f5ac3b1f2,
title = "Amantadine Use for Postconcussion Syndrome",
abstract = "The development of postconcussion syndrome after traumatic brain injury can result in a wide range of potentially debilitating symptoms that includes headaches, cognitive dysfunction, and mood disorders. Unfortunately, data on helpful medications are quite limited, particularly on the treatment of persistent headaches attributed to trauma. This retrospective medical record review used data collected from patients with a diagnosis of postconcussion syndrome in Mayo Clinic's Neurology and Physical Medicine and Rehabilitation outpatient clinics to evaluate the response of postconcussive symptoms to amantadine. A complete trial of amantadine was defined as 100 mg twice per day for 2 months. Thirty-three patients were prescribed amantadine for postconcussive syndrome after traumatic brain injury. One-third of patients discontinued the medication because of adverse effects. However, posttraumatic headaches were improved in 80{\%} of patients who completed a full trial of amantadine. Surprisingly, patients had improvement in headaches even if the medication was prescribed years after the initial trauma. Little improvement was noted in other symptoms such as poor memory, dizziness, and personality changes. Although additional research is certainly needed, amantadine may be a reasonable medication to consider for the treatment of persistent headaches attributed to trauma, even if the initial injury is remote.",
author = "Carabenciov, {Ivan D.} and Bureau, {Britta L.} and Michael Cutrer and Rodolfo Savica",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.mayocp.2018.10.021",
language = "English (US)",
volume = "94",
pages = "275--277",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Amantadine Use for Postconcussion Syndrome

AU - Carabenciov, Ivan D.

AU - Bureau, Britta L.

AU - Cutrer, Michael

AU - Savica, Rodolfo

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The development of postconcussion syndrome after traumatic brain injury can result in a wide range of potentially debilitating symptoms that includes headaches, cognitive dysfunction, and mood disorders. Unfortunately, data on helpful medications are quite limited, particularly on the treatment of persistent headaches attributed to trauma. This retrospective medical record review used data collected from patients with a diagnosis of postconcussion syndrome in Mayo Clinic's Neurology and Physical Medicine and Rehabilitation outpatient clinics to evaluate the response of postconcussive symptoms to amantadine. A complete trial of amantadine was defined as 100 mg twice per day for 2 months. Thirty-three patients were prescribed amantadine for postconcussive syndrome after traumatic brain injury. One-third of patients discontinued the medication because of adverse effects. However, posttraumatic headaches were improved in 80% of patients who completed a full trial of amantadine. Surprisingly, patients had improvement in headaches even if the medication was prescribed years after the initial trauma. Little improvement was noted in other symptoms such as poor memory, dizziness, and personality changes. Although additional research is certainly needed, amantadine may be a reasonable medication to consider for the treatment of persistent headaches attributed to trauma, even if the initial injury is remote.

AB - The development of postconcussion syndrome after traumatic brain injury can result in a wide range of potentially debilitating symptoms that includes headaches, cognitive dysfunction, and mood disorders. Unfortunately, data on helpful medications are quite limited, particularly on the treatment of persistent headaches attributed to trauma. This retrospective medical record review used data collected from patients with a diagnosis of postconcussion syndrome in Mayo Clinic's Neurology and Physical Medicine and Rehabilitation outpatient clinics to evaluate the response of postconcussive symptoms to amantadine. A complete trial of amantadine was defined as 100 mg twice per day for 2 months. Thirty-three patients were prescribed amantadine for postconcussive syndrome after traumatic brain injury. One-third of patients discontinued the medication because of adverse effects. However, posttraumatic headaches were improved in 80% of patients who completed a full trial of amantadine. Surprisingly, patients had improvement in headaches even if the medication was prescribed years after the initial trauma. Little improvement was noted in other symptoms such as poor memory, dizziness, and personality changes. Although additional research is certainly needed, amantadine may be a reasonable medication to consider for the treatment of persistent headaches attributed to trauma, even if the initial injury is remote.

UR - http://www.scopus.com/inward/record.url?scp=85060690059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060690059&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.10.021

DO - 10.1016/j.mayocp.2018.10.021

M3 - Article

C2 - 30711125

AN - SCOPUS:85060690059

VL - 94

SP - 275

EP - 277

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -